Apr 28, 2023
|
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
|
|
Apr 05, 2023
|
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
|
|
Mar 20, 2023
|
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
|
|
Mar 16, 2023
|
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
|
|
Mar 08, 2023
|
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
|
|
Feb 07, 2023
|
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
|
|
Feb 02, 2023
|
AC Immune to Present at the SVB Securities Global Biopharma Conference
|
|
Jan 26, 2023
|
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
|
|
Jan 18, 2023
|
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
|
|